CellCentric

Inobrodib (CCS1477): first-in-class p300/CBP small molecule inhibitor drug, to treat specific cancers.

[CellCentric @CellCentric]

Updated Phase 2 data at #EHA2026! Next week in Stockholm, we are excited to be presenting updated results from our randomized Phase 2 dose optimization study of inobrodib + pom/dex (InoPd) in relapsed/refractory #multiplemyeloma. Visit us at Booth # H2.03!

[CellCentric @CellCentric]

We’re excited to announce the launch of https://t.co/kw4EGXw92J, a new resource for U.S. HCPs. Explore the science behind inobrodib's novel mechanism of action, learn about ongoing clinical trials, and hear from the MM community.

[CellCentric @CellCentric]

CellCentric looks forward to engaging with the #oncology community at #ASCO26 as we share ongoing progress in the development of inobrodib, our first-in-class investigational oral p300/CBP inhibitor for #multiplemyeloma. See you in Chicago!

[CellCentric @CellCentric]

We’ve closed an oversubscribed $220M Series D financing to advance pivotal trials of inobrodib in #multiplemyeloma. Led by @Venrock, this funding reflects strong conviction in inobrodib’s potential to address a critical need after BCMA/TCE therapies. More: https://t.co/sdfNQnOisV

[CellCentric @CellCentric]

Inobrodib is a first-in-class oral therapy designed to target p300/CBP - proteins that play an important role in driving #multiplemyeloma. By binding to and displacing p300/CBP, inobrodib reduces the expression of key cancer drivers MYC and IRF4.

[CellCentric @CellCentric]

By approaching the same pathway through distinct mechanisms, the combo of ino+pom has potential to drive meaningful responses in #MM, supporting our focus on advancing a novel oral treatment option, particularly for those who have already had an antibody-based therapy (BCMA/TCE).

[CellCentric @CellCentric]

Last month, our transatlantic team took part in the Walk of Light Step Challenge, organized by @bloodcancer_uk. Together, we took more than 11 million steps, surpassing the amount of steps between our UK/US offices, while helping raise awareness of blood cancers, including MM.

[CellCentric @CellCentric]

We’re excited to announce the initiation of DOMMINO-1, our pivotal Phase 2 trial of inobrodib + pom + dex (InoPd) in relapsed/refractory multiple myeloma. The first patient has been dosed, and enrollment is underway across the UK and US. Details: https://t.co/5JQIwzVHsk

[CellCentric @CellCentric]

Majority of heavily pretreated relapsed/refractory #MM patients receive care in community settings. Inobrodib is our investigational oral drug + novel MoA. Delivered with pom/dex, we aim to address an unmet need for people who relapsed or weren’t eligible for TCE/BCMA agents.

[CellCentric @CellCentric]

We strive to maintain a workplace where we show up for one another & the people with cancer we aim to serve. On #EmployeeAppreciationDay, we celebrate our team. Together, we move toward our shared vision to improve the lives of those with cancer. Join us: https://t.co/jqjS8SqSU3

[CellCentric @CellCentric]

MM is a complex blood cancer that remains incurable for many. On #RareDiseaseDay, we recognize the individuals, families and communities impacted and the ongoing need for better, longer-lasting treatment options. We’re proud to be working to reshape care for rare cancers like MM.

[CellCentric @CellCentric]

CellCentric is headed to 📍Boston next week! We look forward to connecting with the investor community to share our progress advancing inobrodib, our first-in-class investigational oral therapy for the treatment of #multiplemyeloma.

[CellCentric @CellCentric]

Inobrodib is our investigational oral drug with a novel MoA. Delivered as a capsule, and used as part of an all-oral regimen with pom/dex (InoPd) for later line patients, it suits community-based care + may improve access for those with later stage #MM. Pivotal studies this year.

[CellCentric @CellCentric]

We have a deep appreciation for the women in STEM who drive innovation forward. On #IDWGS, we’re proud to recognize the women at CellCentric whose expertise, collaboration and commitment help advance science for people living with #multiplemyeloma. Learn more below. #WomeninSTEM

[CellCentric @CellCentric]

Every person’s experience with cancer is unique. That belief drives our people-centered approach: listening, understanding the needs of those impacted by #cancer and advancing innovation for communities with significant unmet need, including #MM. #WorldCancerDay #UnitedByUnique

[CellCentric @CellCentric]

CellCentric is headed to San Francisco for #JPM26! We look forward to connecting with the healthcare community and partners who share our vision for addressing unmet needs in #multiplemyeloma through novel, differentiated innovation. See you there!

[CellCentric @CellCentric]

As an all-oral regimen, InoPd has potential to enhance how #MM is managed in the community setting, where 70%+ of patients are treated. A well-tolerated and accessible treatment option, we believe InoPd could transform care for patients after, or instead of, BCMA/TCE agents.

[CellCentric @CellCentric]

New Phase 2 data at #ASH25 from our investigational, all-oral therapy InoPd (inobrodib + pom/dex) show promising clinical efficacy & tolerable safety profile in heavily pretreated patients with relapsed/refractory #MM. Initial positioning, after bispi. https://t.co/70hfPWz4mb

[CellCentric @CellCentric]

Many #MM patients either are ineligible for a bispecific or cannot tolerate the treatment within the first few months. More to come @ #ASH25 from our Phase 2 expansion arm data of InoPd, with potential to address a major unmet need in the post-BCMA/TCE therapy patient population.

[CellCentric @CellCentric]

Many patients have no other options after relapsing on or not tolerating BCMA/TCE therapies; this is a significant new unmet need in long-term #MM care. With a novel MoA & all-oral regimen, InoPd can help reduce burden, support equity & give patients control. More @ #ASH25.